Rituximab in the management of refractory myasthenia gravis Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Myasthenia Gravis

abstract

  • Myasthenia gravis (MG) is an immune-mediated disorder with a variable response to treatment. In this study, patients with refractory MG who were treated with rituximab were identified. A review of patients referred to the Yale Neuromuscular Clinic was performed. Patients with refractory MG who were treated with rituximab were reviewed for response to treatment. Patients who had muscle-specific kinase (MuSK(+)) or acetylcholine receptor (AChR(+)) antibodies were included. Six patients were identified who met the criteria described. All patients tolerated rituximab without side effects and had a reduced need for immunosuppressants and/or improvement in clinical function. Patients with refractory MG appeared to respond to rituximab in this small, retrospective study. This result suggests that a larger, prospective trial is indicated.

publication date

  • March 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/mus.21521

PubMed ID

  • 19852027

Additional Document Info

start page

  • 375

end page

  • 8

volume

  • 41

number

  • 3